Core--Histology/ Immunohistochemistry/ In Situ Hybridization

此核心的主要目的是为以下项目提供公共设施和专业知识 解释基因治疗可能需要的广泛的形态研究 学习。这一核心的其他主要功能包括抗体和DNA和RNA探针的特征，这可能有助于在正常和基因操作的组织中识别细胞类型或定位感兴趣的分子，以及开发对现有形态技术的增强，这将提高中心研究人员在组织切片中定位特定分子的能力。该核心提供的主要形态技术包括常规组织学，包括特殊组织学染色、免疫组织化学、免疫荧光显微镜、组织酶组织化学、电子显微镜、免疫电子显微镜、原位杂交，以及必要的辅助技术，如Western、Southern和Northern印迹以及抗体结合和竞争抑制分析，以确保所有拟议程序的敏感性和特异性。随着华盛顿大学的整个基因治疗计划的发展，临床前试验的病理学分析得到了更多的重视，并感谢对符合FDA批准进入临床试验的标准的研究设计和动物毒性研究的细微差别的帮助。Denny Liggitt博士已被招募到这一核心，专门解决这一需求。

The principal purpose of this Core is to provide a common facility and expertise for the broad spectrum of morphologic studies that may be required for interpretation of gene therapy studies. Additional major functions of this Core include the characterization of antibodies and DNA and RNA probes that may be useful for the identification of cell types or localization of molecules of interest in normal and genetically manipulated tissues, and the development of enhancements to existing morphologic techniques that will improve the ability of Center investigators to localize specific molecules in tissue sections. The principal morphologic techniques provided by this Core include routine histology, including special histologic stains, immunohistochemistry, immunofluorescence microscopy, tissue enzyme histochemistry, electron microscopy, immunoelectron microscopy, in situ hybridization, and necessary ancillary techniques such as Western, Southern and Northern blotting and antibody binding and competitive inhibition assays needed to ensure the sensitivity and specificity of all proposed procedures. As the entire gene therapy program at the University of Washington has evolved, a greater emphasis has been placed on pathology analyses of pre-clinical trials, with an appreciation for assistance with nuances of study design and animal toxicity studies that would meet FDA standards for approval to progress to clinical trials. Dr. Denny Liggitt has been recruited into this core to specifically address this need.